Reuters logo
Shionogi applies for HIV drug approval in U.S., Europe
December 18, 2012 / 2:21 AM / 5 years ago

Shionogi applies for HIV drug approval in U.S., Europe

TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir.

Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below